Pharmacological profile of novel cyclic analogs of 2-amino-7-phosphonoheptanoic acid.
Ferkany
J W
JW
Nova Pharmaceutical Corporation, CNS Pharmacology, Baltimore, Maryland 21224.
Kyle
D J
DJ
Ellenberger
W P
WP
Narayanan
B A
BA
Ellenberger
S R
SR
Hudkins
R
R
Guzewska
M E
ME
Rzeszotarski
W J
WJ
Conti
L
L
Patch
R
R
D015763:2-Amino-5-phosphonovalerate / Q000031:analogs & derivatives*; D000596:Amino Acids / Q000494:pharmacology* / Q000633:toxicity; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology* / Q000633:toxicity; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004597:Electroshock; D008297:Male; D051379:Mice; D016202:N-Methylaspartate / Q000494:pharmacology; D010433:Pentylenetetrazole / Q000494:pharmacology; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects* / Q000502:physiology; D012640:Seizures / Q000139:chemically induced / Q000503:physiopathology*; D013329:Structure-Activity Relationship
D000596:Amino Acids; D000927:Anticonvulsants; D016194:Receptors, N-Methyl-D-Aspartate; C060212:NPC 12626; D016202:N-Methylaspartate; D015763:2-Amino-5-phosphonovalerate; C031231:2-amino-7-phosphonoheptanoic acid; D010433:Pentylenetetrazole